Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed the submission of its Audit Report for FY2024, receiving an ‘Unqualified’ audit opinion from Samil PricewaterhouseCoopers for both consolidated and separate financial statements. Consolidated revenue reached KRW 4.547T, with an operating profit of KRW 1.320T.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Submission of Audit Report
- External Auditor Name: Samil PricewaterhouseCoopers
- Audit Report Receipt Date: February 25, 2025
- Audit Opinions & Key Considerations:
- Consolidated Audit Opinion: Unqualified (Prior year: Unqualified)
- Separate Audit Opinion: Unqualified (Prior year: Unqualified)
- Going Concern Uncertainty: Not applicable
- Internal Accounting Control System Non-Unqualified Opinion Status: Not applicable
- Embezzlement/Breach of Trust Disclosures: No
- Consolidated Financial Performance (FY2024, Unit: KRW):
- Total Assets: 17,336,296,349,511
- Total Liabilities: 6,431,620,287,493
- Total Equity: 10,904,676,062,018
- Capital Stock: 177,935,000,000
- Revenue: 4,547,322,176,421
- Operating Profit: 1,320,052,380,133
- Profit Before Income Tax: 1,370,051,625,753
- Net Profit: 1,083,315,885,986
- Number of Consolidated Subsidiaries: 14 (Major subsidiaries: 1)
- Separate Financial Performance (FY2024, Unit: KRW):
- Total Assets: 13,317,210,924,810
- Total Liabilities: 4,036,318,163,152
- Total Equity: 9,280,892,761,658
- Revenue: 3,497,145,675,782
- Operating Profit: 1,321,425,521,850
- Net Profit: 1,050,966,501,040
- Other Important Details:
- The financial statements in the audit report are subject to final approval at the upcoming General Meeting of Shareholders and may undergo changes during the approval process.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Receipt of Unqualified Audit Opinion and Shareholder Approval
This disclosure provides notice of the submission of the FY2024 audit report, featuring an ‘Unqualified’ opinion issued by Samil PricewaterhouseCoopers.
Monitoring whether the financial statements are finalized without changes during the Annual General Meeting of Shareholders and tracking the upcoming Annual Report filing is essential.
Relevant details can be verified in the subsequent Results of AGM disclosure and the upcoming Annual Report.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
